USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: TISSUETECH, INC.
City: MIAMI
State: FL
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,028,209.00 7
SBIR Phase II $3,852,976.00 4

Award List:

DEVELOPMENT OF SUTURELESS AMNIOTIC MEMBRANE GRAFT

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scheffer C. Tseng
Award Amount: $103,123.00
Abstract:
DESCRIPTION (provided by applicant): Ever since Pl's first report in 1995 to reintroduce the use of human preserved amniotic membrane for ocular surface reconstruction, there has been a surge of interest in its ophthalmic uses as evidenced by the increasing numbers of papers published. Collectively,… More

EX VIVO EXPANSION OF RPE CELLS FOR TRANSPLANTATION

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scheffer C. Tseng
Award Amount: $117,107.00
Abstract:
Retinal pigment epithelial cells (RPE) play a pivotal role in maintaining retinal function. Dysfunction of RPE contributes to the pathogenesis of age-related macular degeneration (ARMD), which accounts for the major cause of permanent visual loss after age 55 years in Western countries. Conventional… More

DEVELOPMENT OF SUTURELESS AMNIOTIC MEMBRANE GRAFT

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Scheffer C. Tseng
Award Amount: $730,591.00
Abstract:
DESCRIPTION (provided by applicant): Due to the Principal Investigator's pioneering work over the past decade, amniotic membrane transplantation (AMT) for ocular surface reconstruction was approved by the FDA in 2001 and reimbursed by Medicare in 2004 as a standard surgical procedure. A number of… More

ANTI-SCARRING AND ANTI-INFLAMMATORY EFFECTS OF AMNIOTIC MEMBRANE EXTRACTS

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scheffer C. Tseng
Award Amount: $113,098.00
Abstract:
DESCRIPTION (provided by applicant): Due to the Pi's pioneering work over the past decade, amniotic membrane transplantation (AMT) for ocular surface reconstruction was approved by the FDA in 2001 and reimbursed by Medicare in 2004 as a standard surgical procedure. A number of studies have shown… More

Tea Tree Oil for Treating Ocular Demodex Infestation

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scheffer C. Tseng
Award Amount: $112,409.00
Abstract:
DESCRIPTION (provided by applicant): Demodex (folliculorum and brevis) mites are microscopic ectoparasites that commonly infest the pilosebaceous unit of the skin. Uncontrolled overgrowth of these mites has been implicated in causing rosacea in the face, b lepharitis in the eyelid, and other… More

Amniotic Membrane Patch Graft to Cover Glaucoma Drainage Tube

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hosam Elsheha
Award Amount: $131,928.00
Abstract:
DESCRIPTION (provided by applicant): Glaucoma drainage devices (GDDs) have widely been used in the treatment of high risk refractory glaucoma. To avoid tube exposure, which may lead to serious eye infection, the implanted GDD tube has to be covered by a pa tch graft made of donor sclera or… More

Phase II: Anti-inflammatory and Anti-scarring Actions of Amniotic Membrane Extra

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Scheffer C. Tseng
Award Amount: $935,580.00
Abstract:
DESCRIPTION (provided by applicant): Over the past decade, there has been a surge of interest in amniotic membrane transplantation (AMT) for ocular surface reconstruction. A number of studies have shown that AMT using cryopreserved AM (AmnioGraft(R)) manuf actured by Bio-Tissue, Inc., a subsidiary… More

Anti-angiogenesis of HC-HA Covalent Complex and PTX3 Purified from Fetal Membrane

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scheffer C. Tseng – 305-274-1299
Award Amount: $239,951.00
Abstract:
DESCRIPTION (provided by applicant): Angiogenesis is a part of adult wound healing, which starts from inflammation and may end in scarring. When inflammation, angiogenesis, and scarring are well controlled, adult wound healing results in the restoration oftissue function. In contrast, pathologic… More

Safety and Efficacy of Single-use Cliradex Pads for Ocular Mites

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Scheffer C. Tseng – 305-274-1299
Award Amount: $1,189,673.00
Abstract:
DESCRIPTION (provided by applicant): Demodex mites are microscopic ectoparasites that commonly infest the pilosebaceous unit of the skin. Uncontrolled overgrowth of mites has been implicated in causing papulopustular lesions in the skin, rosacea in the face, and blepharitis in the eye. Blepharitis… More

Amniotic Membrane versus Pericardium in Reducing Glaucoma Drainage Tube Exposure

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Hosam El sheha – 305-412-4431
Award Amount: $997,132.00
Abstract:
DESCRIPTION (provided by applicant): Glaucoma drainage devices (GDDs) have widely been used in the treatment of high-risk refractory glaucoma. To avoid tube exposure, which may lead to serious eye infection, the implanted GDD tube must be covered by apatch graft traditionally made of either… More

Engineering of Human Corneal Endothelial Grafts

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ying T. Zhu – 305-412-4430
Award Amount: $210,593.00
Abstract:
DESCRIPTION (provided by applicant): The corneal endothelium plays a pivotal role in maintaining corneal transparency. Unlike other species, the human corneal endothelium is notorious for its limited proliferative capacity in vivo after injury, aging, andsurgery. Persistet corneal endothelial… More